- Investor Overview
- Stock Information
- News Releases
- Events & Presentations
- SEC Filings
- STOCKHOLDER MEETINGS
AND PROXY MATERIALS
- Corporate Governance
- Contact Jaguar IR
|View printer-friendly version|
|Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger|
Merger Terms Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus
Jaguar to Host Conference Call
The merger transaction remains on track to become effective on
“Today’s votes represent a pivotal development in the evolution of both
companies. It is truly transformational for
The Jaguar management team will host a call on
For interested individuals unable to join the conference call, a replay
of the webcast will be available on the investor relations section of
Jaguar’s website (click
here) for 90 days following the call. Also, a dial-in replay of the
call will be available through
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
For more information, please visit www.napopharma.com.
For more information about Jaguar, please visit http://www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the benefits of the merger between Jaguar and Napo, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and Jaguar’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
|Print Page | Email Page | RSS Feeds | Email Alerts | Financial Tear Sheet|